Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPci-pal Regulatory News (PCIP)

Share Price Information for Pci-pal (PCIP)

Share Price is delayed by 15 minutes
Get Live Data
49.00    0.00 (0.00%)
Bid:
48.00
Ask:
50.00
Spread: 2.00 (4.167%)
Market Cap: £35.50m
PCIP Live PriceLast checked at - London Stock Exchange

Intraday Pci-pal Share Chart

Patent Case Update

10 Nov 2021 07:00

RNS Number : 8561R
PCI-PAL PLC
10 November 2021
 

 

PCI-PAL PLC

("PCI Pal", "the Company" or "the Group")

Patent Case Update

 

PCI-PAL PLC (AIM: PCIP), the global cloud provider of secure payment solutions for business communications, provides an update on the on-going lawsuit filed by its competitor in the UK and US in September 2021.

 

As notified on 16 September 2021, one of PCI Pal's competitors, the US private equity owned, UK company, Semafone Limited, commenced litigation proceedings against the Company in the UK and the US for alleged patent infringement, which relates to one aspect of how one of the Company's products functions. As previously stated, PCI Pal strongly refutes these claims.

 

PCI Pal has this week filed its UK defence and counterclaim to the UK Court in response to the claims, and has summarised two headline points from this filing below:

 

1. PCI Pal does not infringe the patents as claimed by Semafone;

2. The patent is invalid. It lacks novelty and inventive step over the prior art1;

 

PCI Pal believes that the filing shows a strong defence and, in addition to non-infringement, has provided the Court with information on prior art and invalidity arguments. The Court will assess these points and Semafone's arguments and opine accordingly.

 

In the US, PCI Pal has also started the defence of the claims being made.

 

In the last week, PCI Pal has made an application to the US Court for it to invalidate the Semafone US patents under section 101 of the US Patent Act. The Company believes those patents are overly abstract and thus do not qualify for patentable subject matter under the US patent laws. PCI Pal has made this application to ensure it does not spend significant time and resources on further defence points, based around non-infringement and prior art based invalidity, before having the eligibility of the patents reviewed by the US Court. PCI Pal expects to understand the Court's position on this motion in the next few months.

 

PCI Pal is well funded, with no debt, and given the continued strong trading announced today is in a good position to deal with these allegations. The Group will be reporting costs associated with its defence of these allegations as exceptional items in its accounts.

 

PCI Pal is working with its well-established team of advisors to work towards an outcome that it believes will best benefit the Company, whilst at the same time focusing on delivering its strategic growth plans based on the established momentum within the Group.

 

Given the nature of the claims being made against PCI Pal, it is limited in the information it can provide on the case, but the Board will endeavour to keep investors updated as appropriate.

 

 

1Section 2(1) of the Patents Act 1977 Act states that an invention shall be taken to be new if it does not form part of the state of the art. Section 2(2) then goes on to define the state of the art as to be taken to comprise all matter (whether a product, a process, information about either, or anything else) which has at any time before the priority date of the invention been made available to the public (whether in the UK or elsewhere) by written or oral description, by use or in any other way. This is generally known as "prior art".

 

For further information, please contact:

 

PCI-PAL PLC

Via Walbrook PR

James Barham - Chief Executive Officer

William Good - Chief Financial Officer

 

 

finnCap (Nominated Adviser and Broker)

+44 (0) 20 7227 0500

Marc Milmo/Simon Hicks (Corporate Finance)

Richard Chambers (Corporate Broking)

 

 

Walbrook PR

+44 (0) 20 7933 8780

Tom Cooper/Nick Rome

+44 (0) 797 122 1972

 

PCIPAL@walbrookpr.com

 

About PCI Pal:

 

PCI Pal is a leading provider of Software-as-a-Service ("SaaS") solutions that empower companies to take payments from their customers securely, adhere to strict industry governance, and remove their business from the significant risks posed by non-compliance and data loss. Our products secure payments and data in any business communications environment including voice, chat, social, email, and contact centre. We are integrated to, and resold by, some of the worlds' leading business communications vendors, as well as major payment service providers.

 

The entirety of our product-base is available from our global cloud platform hosted in Amazon Web Services ("AWS"), with regional instances across EMEA, North America, and ANZ.

 

For more information visit www.pcipal.com or follow the team on Linkedin: https://www.linkedin.com/company/pci-pal/

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEAXFNEFDFFFA
Date   Source Headline
14th Apr 20267:00 amRNS-RHIPAA, HITRUST & SOC 2 Type II certification
18th Mar 20267:00 amRNS-RMajor New Reseller Partnership with Global Telco
10th Mar 20263:07 pmRNSHolding(s) in Company
10th Mar 20263:07 pmRNSHolding(s) in Company
3rd Mar 20267:00 amRNSInterim Results, Analyst Briefing & Investor Pres
23rd Feb 20267:00 amRNS-RNew Major Strategic Reseller Partnership
17th Feb 20267:00 amRNSNotice of Results, Analyst Briefing, Investor Pres
10th Feb 20265:07 pmRNSHolding(s) in Company
6th Feb 202611:26 amRNSHolding(s) in Company
6th Feb 202611:25 amRNSHolding(s) in Company
5th Feb 202612:48 pmRNSHolding(s) in Company
3rd Feb 20267:00 amRNSTrading Update
18th Dec 20254:44 pmRNSGrant of Options under Long-Term Incentive Plan
18th Dec 20254:44 pmRNSGrant of Options under Long-Term Incentive Plan
1st Dec 20252:49 pmRNSResult of AGM
19th Nov 20257:00 amRNS-RStrategic US Healthcare Sector Integration
17th Nov 20253:19 pmRNS-RCMD Presentation Video
14th Nov 20257:00 amRNS-RCMD Presentation & MelloLondon
11th Nov 20257:00 amRNSCapital Markets Day
6th Nov 20254:20 pmRNSAnnual Financial Report & Notice of AGM
25th Sep 20258:45 amRNSHolding(s) in Company
9th Sep 20257:00 amRNSFinal Results, Analyst Briefing & Investor Pres
19th Aug 20257:00 amRNSNotice of Results, Analyst Briefing, Investor Pres
30th Jul 20253:18 pmRNSDirector Share Purchases
29th Jul 202510:20 amRNSDirector Share Purchase
29th Jul 20257:01 amRNSTrading & Business Update
29th Jul 20257:00 amRNSNew Product Launch
1st Jul 20257:00 amRNSBoard Changes
20th Jun 202512:00 pmRNSIssue of Equity & TVR
3rd Apr 20259:24 amRNSHolding(s) in Company
12th Mar 20253:20 pmRNSDirector Share Purchases
10th Mar 20257:00 amRNS-RPCI Pal and RingCentral Inc Partnership
6th Mar 20252:00 pmRNSPDMR Issue of Options
4th Mar 20253:49 pmRNSDirector Share Purchase
4th Mar 20257:00 amRNSInterim Results, Analyst Briefing & Investor Pres
18th Feb 20257:00 amRNSNotice of Results, Analyst Briefing, Investor Pres
27th Jan 20257:00 amRNSTrading Update
11th Dec 20242:42 pmRNSHolding(s) in Company
11th Dec 20242:17 pmRNSResult of AGM
11th Dec 20247:00 amRNSAGM Statement
6th Dec 20244:10 pmRNSExercise of Options & TVR
14th Nov 20244:23 pmRNSAnnual Financial Report & Notice of AGM
22nd Oct 20247:00 amRNSFinal Results, Analyst Briefing & Investor Pres
14th Oct 20247:00 amRNSConfirmation of CFO Appointment
19th Sep 20247:00 amRNSAudit Update & Timing of Results
10th Sep 20244:46 pmRNSHolding(s) in Company
28th Aug 20247:00 amRNSTrading Update, New Partner & Notice of Results
22nd Jul 20249:15 amRNSHolding(s) in Company
1st Jul 20245:23 pmRNSExercise of Options, Director Shareholding & TVR
1st Jul 20247:00 amRNSBoard Changes - Appointment of CFO

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.